BHRT for Women

Menopause is the best-known reason a woman seeks hormone therapy, and for many patients it is the reason — but it describes one application of this approach rather than the whole of it. Bioidentical hormone replacement therapy for women means replacing the hormones her own body made, using molecules structurally identical to them, dosed toward a healthy physiological range and monitored as the body responds. The underlying principles are the ones set out on our bioidentical hormone replacement therapy page. What changes patient to patient is which hormone has fallen furthest, how far she is from her final period, and what else is interacting with the result.

That arc runs longer than most women are told to expect. Hormonal change commonly begins in the late thirties or early forties, years before periods stop, and it does not conclude at menopause — the postmenopausal years can call for careful hormone management for a long time afterward. Women who reach menopause abruptly rather than gradually, after a hysterectomy that removed the ovaries or after cancer treatment, meet the same decline compressed into weeks. Younger women can have a genuine deficiency driven by primary ovarian insufficiency, thyroid disease, prolonged stress, or the months after childbirth. Age is not the entry criterion. A consistent pattern of symptoms, with laboratory findings that explain the pattern, is.

Our menopause treatment page covers the life-stage side of this in depth: hot flashes, night sweats, broken sleep, shifting mood. This page is about the hormonal program sitting behind those symptoms — what gets measured, what routinely gets missed, and how the pieces are balanced against each other.

A program built around a single hormone will under-serve a predictable share of the women who try it, because no hormone in this system acts alone. Dr. Riegel evaluates the full panel at baseline and treats what the testing and the symptoms together justify.

Estradiol. The hormone most closely identified with menopause, and the one responsible for vasomotor symptoms, vaginal and urinary tissue changes, and much of the bone loss that follows the final period. Dose and route both matter a great deal here, and the evidence behind estrogen therapy is more nuanced than the 2002 headlines suggested — our estrogen replacement therapy page works through that evidence and the delivery-route decision in detail.

Progesterone. Often the first hormone to fall, because perimenopausal cycles stop ovulating reliably long before estrogen production ends. Low progesterone shows up as insomnia, new anxiety, irritability, and heavier or unpredictable periods. It also carries a safety role: established guidance from The Menopause Society and the American College of Obstetricians and Gynecologists holds that a woman with an intact uterus who takes systemic estrogen needs adequate progesterone or another progestogen to protect the endometrium. Our progesterone therapy page covers that side of the balance.

Thyroid. Fatigue, weight change, cold intolerance, brain fog, hair thinning, and low mood belong to both suboptimal thyroid function and estrogen deficiency, which is how one gets mistaken for the other. The American Thyroid Association estimates women are five to eight times more likely than men to develop thyroid disease, and TSH alone is not enough to settle the question, so free T3, free T4, and antibodies are part of the female panel. Women whose central problem turns out to be the thyroid are treated through our thyroid hormone therapy program.

DHEA and cortisol. DHEA-S is an adrenal precursor that declines steadily with age and contributes to a woman's testosterone supply. Cortisol is the stress hormone that, when it stays elevated, interferes with thyroid hormone conversion and suppresses the signals driving ovulation. Both are measured, and women whose results point that direction are worked up through our adrenal fatigue evaluation, which is deliberately candid about what that label does and does not mean.

Testosterone gets its own section below. Pregnenolone, FSH, SHBG, vitamin D, a metabolic panel, and a complete blood count fill out the baseline. None of it is testing for the sake of testing — every marker changes what Dr. Riegel prescribes, at what dose, and what he watches at follow-up.

Testosterone is widely treated as a male hormone, and that assumption costs women. A woman produces testosterone in her ovaries and adrenal glands, and she circulates it at concentrations well above her estradiol — measured in nanograms where estradiol is measured in picograms. It contributes to libido and sexual response, energy, mood, muscle, and bone. Levels decline gradually from a woman's twenties onward rather than dropping at menopause the way estrogen does, which is one reason the decline goes unnoticed; removal of both ovaries, by contrast, cuts a substantial share of production at once.

The evidence here deserves precision rather than enthusiasm. A global consensus position statement published in 2019 by an international panel — endorsed by eleven professional bodies including The Menopause Society, the International Menopause Society, and the Endocrine Society — concluded that the only indication supported by adequate evidence is hypoactive sexual desire disorder in postmenopausal women: low desire that causes genuine personal distress. The same statement is explicit that treatment should aim at concentrations within the premenopausal physiological range, that products and doses designed for men are not appropriate for women, and that the data are insufficient to support testosterone for any other symptom or for disease prevention.

There is a practical complication that reputable clinics should state plainly: no testosterone product is approved by the FDA specifically for women in the United States, so any prescription for a woman is off-label use of an approved product or a compounded preparation. That raises rather than lowers the standard for the prescriber. Dr. Riegel measures total and free testosterone alongside SHBG before treating, dose-adjusts toward a female physiological range rather than a male one, and monitors for the androgenic effects — acne, unwanted hair growth, scalp hair changes — that signal a level has gone too high. Women whose main complaint is desire and sexual response are evaluated through our low libido treatment program, where testosterone is one consideration among several. The male counterpart to this page, covering the same axis from the other side, is our BHRT for men page.

Where a woman sits on this timeline changes what the testing means, which is why the same lab report can warrant different decisions in two different patients.

In perimenopause, estradiol does not simply fall — it swings. Cycles become anovulatory and irregular, progesterone production drops first, and estrogen can spike above its former range before it settles down. A single estradiol or FSH draw in these years is a snapshot of a moving target, and a woman told her labs are normal has frequently been tested once, at an arbitrary point in an erratic cycle. Dr. Riegel reads perimenopausal results against the symptom history and the timing of the cycle rather than against a reference range alone.

Menopause itself is defined retrospectively, as twelve consecutive months without a period. Vasomotor symptoms are not a brief episode for most women: in the Study of Women's Health Across the Nation, published in JAMA Internal Medicine in 2015, the median total duration of frequent hot flashes and night sweats was roughly 7.4 years, and it ran longer for women whose symptoms began before their final period. Bone loss also accelerates in the years bracketing that final period, which is why bone health is part of the conversation well before a fracture — see our osteoporosis management page.

In the postmenopausal years the question shifts from managing a transition to managing a long-term hormonal state: what dose remains appropriate, whether symptoms have changed, how bone density is tracking, and whether the balance of benefit and risk still favors continuing. That is a periodic review rather than a one-time decision, and it is a large part of what ongoing care consists of.

These three words get used interchangeably in marketing, and conflating them makes it harder for a woman to evaluate what she is being offered. They describe different things.

"Bioidentical" describes the molecule: a hormone with the same chemical structure as the one the body produces. Estradiol and micronized progesterone are both bioidentical, and both are available in commercially manufactured, FDA-approved products — patches, gels, and capsules among them. So a bioidentical prescription is not automatically a compounded one.

“Compounded” describes how a preparation is made: a pharmacy prepares it for an individual prescription, which allows combinations, strengths, and delivery routes that no commercial product offers. That flexibility is the reason compounding exists in hormone medicine, and it is also why compounded preparations sit outside FDA premarket approval. The weight therefore falls on the physician choosing the formulation and on the laboratory follow-up that confirms where levels actually landed. Dr. Riegel's roughly forty proprietary bioidentical formulations — developed across more than three decades of practice, beginning with four years of hormone research at UT Southwestern Medical School — exist for the cases where a fixed commercial dose could not deliver the precision a patient needed, and he matches the route to her absorption and response. Implanted pellets are the one delivery method he generally does not favor, for the reason set out on our hormone pellet therapy page: once a pellet is in place, the dose cannot be reduced for months.

The distinction that does matter clinically is bioidentical versus the synthetic alternatives — conjugated equine estrogens and synthetic progestins are genuinely different molecules from human estradiol and progesterone, and they do not behave identically in the body. Our guide to bioidentical versus synthetic hormones works through that comparison, and our overview of natural hormone replacement options covers the non-prescription approaches women often try first and what the evidence says about them.

A candidate for bioidentical hormone therapy is a woman with a consistent symptom pattern — vasomotor symptoms, disrupted sleep, new anxiety or low mood, brain fog, fatigue, loss of libido, vaginal dryness or discomfort, changing body composition — together with laboratory evidence that a hormone deficiency accounts for it. The symptoms carry as much weight as the numbers; neither is sufficient alone.

Some women should not begin systemic estrogen, or should not begin it without further evaluation first. Guidance from the American College of Obstetricians and Gynecologists and The Menopause Society identifies unexplained vaginal bleeding, a current or past estrogen-sensitive cancer such as breast or endometrial cancer, active or previous venous thromboembolism or a known clotting disorder, prior stroke or heart attack, active liver disease, and pregnancy as circumstances in which systemic estrogen is contraindicated or has to be reconsidered. Dr. Riegel screens for each of these before treatment starts, which is part of why the first evaluation is thorough rather than quick. Women who cannot take systemic estrogen are not automatically out of options — localized treatment and non-estrogen approaches are discussed on their merits.

Timing of initiation also belongs in the candidacy conversation. The 2022 Hormone Therapy Position Statement of The Menopause Society finds the benefit-risk balance favorable for women under 60, or within ten years of the onset of menopause, who have no contraindications, and less favorable for women starting further out. The reasoning behind that conclusion, including what the Women's Health Initiative did and did not show, is laid out on our estrogen replacement therapy page rather than repeated here. Age-appropriate screening — mammography, and bone density testing where it is relevant — continues throughout treatment.

The first appointment is an evaluation, not a sales pitch. Dr. Riegel takes a full history: when symptoms started and how they have changed, cycle pattern or date of the final period, surgical history, family history, medications, sleep, and whatever has already been tried. He then orders the comprehensive female panel described above, timed to the cycle where cycle timing still affects the result.

When the results are back, he reviews them with you in plain language — what is low, what is out of balance with what, and what the findings do not explain. If hormone therapy is appropriate, he designs the protocol from there: which hormones, at what strengths, by which route, with the progestogen component built in for any woman with a uterus. Costs are discussed openly at that point, once an actual protocol exists to price rather than a hypothetical one. Follow-up laboratory work confirms where levels have landed, and the protocol is adjusted against both the numbers and how you report feeling, because the two do not always move together.

The office is at 4975 Preston Park Blvd, Suite 840, Plano, TX 75093, near Preston Road and Park Boulevard, with appointment hours Monday through Thursday, 10:00 AM to 4:00 PM. Women travel in from Frisco, McKinney, Allen, Richardson, Dallas, and across North Texas, and many established patients handle their follow-up visits through our telehealth program with laboratory draws arranged near home, which keeps physician oversight continuous without a drive to Plano for every appointment. If you are still deciding whom to see, our guide to finding a hormone doctor sets out the questions worth asking any clinic first.

Hormone therapy is a course of treatment, not a switch, and a clinic promising a transformation on a fixed schedule is describing marketing rather than medicine. Response varies with which hormones were deficient, how long they had been deficient, the route of delivery, and everything else going on in a woman's health. As a general pattern, sleep and mood tend to register change earliest, vasomotor symptoms respond over the following weeks as levels stabilize, and libido, body composition, and the genitourinary tissue changes take longer and depend more heavily on which hormone was driving them.

What makes the difference is an accurate diagnosis at the start, a protocol matched to the individual, and follow-through on the monitoring. For a fuller account of what tends to change and when, see our guide to how long hormone therapy takes to work. For the other half of an honest conversation, our article on the side effects of hormone replacement therapy covers the risks and the adjustment-period effects in detail, including what the Women's Health Initiative and the two decades of reanalysis that followed it actually found.